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Diacylglycerol - PKC Epsilon - Insulin Receptor as a Key Regulatory Axis of Hepatic and White 




Type 2 diabetes (T2D) is a chronic condition that currently affects 463 million people worldwide 
and is expected to affect 700 million people by the year of 2045. People with T2D suffer from 
many downstream conditions, such as cardiovascular diseases and stroke, vision loss, renal 
function impairment and amputations due to limb extremity damages, and are also much more 
susceptible to severe COVID-19 conditions. This devastating disease not only inflicts severe 
personal suffering on the individuals affected but also inflicts a huge economic burden on the 
society. For example, the annual cost of diagnosed diabetes in United States is estimated to be 
$327B in 2017. Therefore, understanding the mechanisms underlying the pathogenesis of T2D is 
of great importance, and effective therapeutic inventions can then be developed to remediate the 
situation. 
Insulin resistance is the primary characteristic of T2D, where insulin fails to activate 
downstream signaling pathways, causing excessive glucose build-up in the circulation and tissues 
starved from critical nutrients. In the human body, liver serves as the center of numerous 
metabolic functions and is pivotal in regulating glucose homeostasis. Hepatic insulin resistance 
(HIR) significantly contributes to hyperglycemia via increased hepatic glucose output and 
decreased hepatic glucose storage. Understanding the mechanism of HIR is thus critical. 
Nonalcoholic fatty liver disease (NAFLD) is strongly associated with HIR, however, the key lipid 
species and molecular mechanisms linking these conditions are widely debated. We developed 
 
 II 
a subcellular fractionation method to quantify diacylglycerol (DAG) stereoisomers and ceramides 
in the endoplasmic reticulum (ER), mitochondria, plasma membrane (PM), lipid droplets and 
cytosol. Acute knockdown (KD) of diacylglycerol acyltransferase-2 (DGAT2) in liver induced HIR 
in rats. This was due to PM sn-1,2-DAG accumulation, which promoted PKCe activation, and 
insulin receptor kinase (IRK)-T1160 phosphorylation resulting in decreased IRK-Y1162 
phosphorylation. Liver PM sn-1,2-DAG content and IRK-T1160 phosphorylation were also higher 
in humans with HIR. In rats, liver-specific PKCe KD ameliorated high-fat diet (HFD)-induced HIR 
by lowering IRK-T1160 phosphorylation, while liver-specific overexpression of constitutively 
active PKCe-induced HIR by promoting IRK-T1160 phosphorylation. 
White adipose tissue (WAT) is also of great regulatory importance in glucose metabolism. 
Insulin-mediated suppression of WAT lipolysis is an important anabolic function that is 
dysregulated in the state of overnutrition. However, the mechanism of short-term HFD-induced 
WAT insulin resistance is poorly understood. Based on our studies in the liver and preliminary 
studies in the WAT, we hypothesize that a short-term HFD causes WAT insulin resistance through 
a similar mechanism. Increases in PM sn-1,2-DAG content, which promotes PKCe activation, 
impairs insulin signaling by phosphorylating IRK-T1160. To test this hypothesis, we assessed 
WAT insulin action in 7-day HFD-fed versus regular chow diet-fed rats during a hyperinsulinemic-
euglycemic clamp. HFD feeding caused WAT insulin resistance, reflected by reductions in both 
insulin-mediated WAT glucose uptake and suppression of WAT lipolysis. These changes were 
specifically associated with increased PM sn-1,2-DAG content, increased PKCe activation and 
impaired insulin-stimulated IRK-Y1162 phosphorylation. In order to examine the role of IRK-
T1160 phosphorylation in mediating lipid-induced WAT insulin resistance, we examined these 
same parameters in short-term HFD-fed IRKT1150A mice (IRK-T1150 is the mouse homolog of 
human IRK-T1160). Similar to the rat study, short-term HFD feeding induced WAT insulin 
resistance in WT control mice but failed to induce WAT insulin resistance in IRKT1150A mice. 
 
 III 
Taken together these data demonstrate that the PM sn-1,2-DAG - PKCe - IRK-T1160 
phosphorylation pathway plays an important role in mediating lipid-induced hepatic and WAT 
insulin resistance and represents a potential therapeutic target to improve insulin sensitivity in the 
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The postprandial rise in plasma insulin concentration activates hepatic insulin signaling pathways 
(Figure 1), which promote the storage of ingested carbohydrates into hepatic glycogen and 
suppress endogenous glucose production (EGP) to maintain normoglycemia within a relatively 
narrow range. Decreased hepatic insulin action disrupts these processes and contributes to 
fasting and postprandial hyperglycemia in type 2 diabetes (T2D) [1]. While the cellular and 
molecular mechanisms responsible for hepatic insulin resistance (HIR) are unresolved, ectopic 
lipid accumulation in the liver, leading to nonalcoholic fatty liver disease (NAFLD), is strongly 
associated with HIR and often precedes the development of T2D [2]. However, the key lipid 
species and molecular mechanisms by which ectopic lipids mediate HIR are widely debated, with 
pathways mediated by DAGs and ceramides positioned at the center of this controversy [3-5]. 
Diacylglycerols (DAGs), the penultimate intermediate in triglyceride synthesis, have been 
shown to be highly associated with hepatic steatosis and HIR in both rodents and humans [6-12]. 
In liver, DAGs have been proposed to induce HIR by activating PKCe [8, 13-15]. When activated, 
PKCe phosphorylates T1160, a key threonine residue on insulin receptor kinase (IRK), which is 
situated between two critical IRK activation sites, Y1158 and Y1162, to destabilize IRK’s activation 
loop [16]. However, there are still gaps in this mechanistic model and experimental support 
establishing the direct causal relationship between DAG accumulation and the development of 
HIR is lacking. Further, the role of hepatic PKCe and IRK-T1160 phosphorylation in regulating 
hepatic glucose metabolism has recently been challenged [17]. 
Among three DAG stereoisomers (sn-1,2-DAG, sn-2,3-DAG and sn-1,3-DAG), sn-1,2-
DAG was shown to be the only stereoisomer that activates novel PKCs [18-20] and therefore is 
potentially the key DAG stereoisomer that is responsible for impeding insulin signaling. In addition, 
the subcellular distribution of DAGs is likely important in this regard. For example, in mouse 
models of hepatic CGI-58 KD and Hdac3 depletion, accumulation of lipid droplet DAGs are not 
associated with HIR [21, 22]. Therefore, it is essential to determine the associations between 
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subcellular DAG stereoisomer content, liver-specific PKCe activity, IRK-T1160 phosphorylation 






Figure 1. Hepatic Insulin Signaling 
The binding of insulin triggers insulin receptor’s activation through its dimerization and 
autophosphorylation on critical tyrosine residues. Activated insulin receptor recruits and activates 
























To address the questions on the associations between subcellular diacylglycerol (DAG) 
stereoisomer content, liver-specific PKCe activity, insulin receptor kinase (IRK)-T1160 
phosphorylation and hepatic insulin action in vivo, we developed a liquid-chromatography tandem 
mass spectrometry (LC-MS/MS) method to quantify DAG stereoisomers, as well as ceramides in 
five hepatocellular compartments: endoplasmic reticulum (ER), mitochondria, plasma membrane 
(PM), lipid droplet and cytosol. We then applied these methods in combination with in vivo 
assessment of hepatic insulin signaling (pIRK-T1160, pIRK-Y1162, pAkt-S473, pGSK3β-S9 and 
pFOXO1-S256 and endogenous glucose production (EGP), utilizing the hyperinsulinemic-
glucose clamp technique, in awake rats with acute liver-specific diacylglycerol acyltransferase-2 
(DGAT2) knockdown (KD) to acutely raise hepatic DAG content. Next, in order to determine if the 
results translate to humans, we quantified liver DAG stereoisomers and ceramides in the five 
subcellular compartments as well as pIRK-T1160 in humans with and without nonalcoholic fatty 
liver disease (NAFLD) and hepatic insulin resistance (HIR). Finally, in order to determine the role 
of PKCe in regulating hepatic insulin signaling, we assessed hepatic glycogen synthesis, EGP 
and hepatic insulin signaling in liver-specific PKCe KD rats and rats with liver-specific 
overexpression (OE) of constitutively activated PKCe. Using this comprehensive approach, we 
show that an accumulation of PM sn-1,2-DAG content is sufficient to cause HIR at the level of 
IRK, which in turn could be attributed to activation of PKCe and phosphorylation of IRK-T1160 in 






Acute Hepatic DGAT2 KD Induces HIR 
DGAT2 is the critical ER-located enzyme that catalyzes the esterification of DAGs with acyl-CoAs 
to produce triglyceride. We previously reported that chronic hepatic DGAT2 KD paradoxically 
reverses high-fat diet (HFD)-induced DAG accumulation and HIR, at least partially due to 
suppression of SREBP-1c-mediated lipogenesis [23]. However, we hypothesized that an acute 
DGAT2 KD might provide a narrow window in which DAGs transiently accumulate, allowing us to 
further delineate their association with PKCe activation and HIR. To test this hypothesis, we dosed 
regular chow-fed male Sprague Dawley rats with an antisense oligonucleotide (ASO) targeting 
DGAT2. Two days after the dosing, liver DGAT2 protein content was ~50% lower in acute hepatic 
DGAT2 KD rats compared to the control group and no KD effect was observed in white adipose 
tissue (WAT) (Figure 2A). During a hyperinsulinemic-euglycemic clamp (Figures 3A-3D), the 
acute hepatic DGAT2 KD impaired insulin’s ability to suppress EGP (Figure 2B). Acute hepatic 
DGAT2 KD impaired hepatic insulin signaling at the level of IRK. Insulin-stimulated IRK-Y1162 
phosphorylation was >50% lower and was accompanied by impaired downstream insulin-
stimulated Akt-S473, GSK3β-S9 and FOXO1-S256 phosphorylation in acute hepatic DGAT2 KD 
rats compared to the control group (Figure 2C). This defect in hepatic insulin signaling was 
associated with ~2-fold higher PKCe activation (Figure 2D).  PKCe has been previously shown to 
phosphorylate IRK at T1160 to impair hepatic insulin signaling [16]. We used a phospho-specific 
monoclonal antibody to assay the phosphorylation of this residue in liver and observed ~75% 












Figure 2. Acute Hepatic DGAT2 KD Induces HIR 
(A) Hepatic and WAT DGAT2 protein content measured by western blot (top) and with its 
quantification (bottom). 
(B) EGP and its suppression by insulin during a hyperinsulinemic-euglycemic clamp in Ctrl versus 
acute hepatic DGAT2 KD rats. 
(C) Levels of insulin-stimulated liver pIRK-Y1162, pAkt-S473, pGSK3β-S9 and pFOXO1-S256 as 
measured by western blot (top) and with its quantification (bottom).  
(D) Liver PKCe translocation from cytosol to membrane as measured by western blot (top) and 
with its quantification (bottom). 
(E) Levels of liver pIRK-T1160 in Ctrl versus acute hepatic DGAT2 KD rats as measured by 
western blot (top) and with its quantification (bottom). 
In all panels, data are the mean±S.E.M. In (A), (C) and (E), n = 6 per group. In (B), n = 8 per 















Figure 3. Hepatic DGAT2 KD Hyperinsulinemic-Euglycemic Clamp 
(A) Fasted body weight, fasting and clamp insulin levels, plasma glucose and glucose infusion 
rate during hyperinsulinemic-euglycemic clamp in Ctrl versus DGAT2 KD rats. 
(B) Plasma NEFA and its suppression by insulin during clamp. 
(C) Insulin-stimulated whole-body glucose turnover during clamp. 
(D) Liver triglyceride content in Ctrl versus DGAT2 KD rats. 




Liver PM sn-1,2-DAG Content Tracks with HIR in Rats and Humans 
Next to examine the associations of DAG stereoisomer content in different subcellular 
compartments with HIR, we separated liver tissues into ER, mitochondria, PM, lipid droplet and 
cytosol using differential centrifugation (Figures 4A and 5A) and measured their DAG 
stereoisomer content utilizing a novel LC-MS/MS method (Figure 4B). Acute hepatic DGAT2 KD 
caused the sn-1,2-DAG content to be ~50% higher in the ER and ~80% higher in the PM (Figure 
4C). In contrast, there were no discernible differences observed for sn-2,3- and sn-1,3-DAGs 
(Figures 4D and 4E). We also observed slightly higher hepatic cytosolic C16:0, C22:0 and C24:0 
ceramide content following acute DGAT2 KD, potentially due to substrate (acyl-CoA) 
accumulation (Figure 5B). In order to determine if these results would translate into humans, we 
also examined liver tissues from a cohort of human individuals who were either hepatic insulin-
sensitive or hepatic insulin-resistant as previously characterized using hyperinsulinemic clamp 
methodology (Table 1) [6]. Consistent with the results in rodents, liver PM sn-1,2-DAG content 
was ~5-fold higher in individuals with HIR and NAFLD compared to individuals without HIR (Figure 
4F), without discernible differences in ceramide content (Figure 5C). Furthermore, the higher PM 
sn-1,2-DAG content was associated with an ~3-fold higher level of pIRK-T1160 in individuals with 











Figure 4. Liver PM sn-1,2-DAG Content Tracks with HIR in Rats and Humans 
(A) Separation of five subcellular compartments in liver measured by western blot. 
(B) Representative chromatogram (n = 13) of DAG stereoisomer separation on LC-MS/MS. 
(C) Liver sn-1,2-DAG, (D) liver sn-2,3-DAG, and (E) liver sn-1,3 DAG content in five subcellular 
compartments in Ctrl versus DGAT2 KD rats. 
(F) Liver sn-1,2-DAG, (G) liver sn-2,3-DAG, and (H) liver sn-1,3-DAG content in five subcellular 
compartments in human individuals who were insulin-sensitive (black) or insulin-resistant (red). 
In all panels, data are the mean±S.E.M. In (C), (D) and (E), n = 8 per group. In (F), (G) and (H), 










Figure 5. Subcellular Content of Lipids in DGAT2 KD Rats and Human Subjects 
(A) Liver DAG stereoisomer content measured with and without the fractionation method to 
determine the lipid content recovery of the fractionation method. 
(B) and (C) Liver ceramide species content in five subcellular compartments. 
(D) Human liver IRK-T1160 phosphorylation as measured by western blot (top) and with its 
quantification (bottom). 
In all panels, data are the mean ± SEM. In (A), n = 3 per group. In (B), n = 8 per group. In (C), n 














Liver-Specific PKCe KD Ameliorates HFD- and Acute DGAT2 KD-Induced HIR 
A recent study in liver-specific PKCe knockout mice challenged the notion that hepatic PKCe 
activation is required for the development of lipid-induced HIR [17], seemingly refuting a prior 
study using 2’-O-methoxyethyl (2’-MOE) ASO against PKCe in which the KD of both hepatic and 
WAT PKCe were associated with improvements in hepatic and WAT insulin action in awake rats 
[13]. To further examine the role of PKCe in regulating insulin action in the liver, we used a next-
generation 2’-MOE ASO additionally modified with N-acetyl galactosamine (GalNAc). GalNAc 
modification facilitates ASO’s delivery into hepatocytes [24], permitting liver-specific PKCe KD in 
adult rats over the course of 3-week ASO dosing. MOE-GalNAc-modified PKCe ASO lowered 
liver PKCe protein content by ~70% without altering WAT PKCe protein content (Figure 6A). 
Insulin action was then assessed in these rats after a 4-day HFD feeding which is a common 
model to induce acute hepatic steatosis and HIR. During a hyperinsulinemic-hyperglycemic clamp 
(Figures 7A-7F), liver-specific PKCe KD improved insulin’s ability to suppress EGP (Figure 6B). 
We chose to use hyperinsulinemic-hyperglycemic clamp since both hyperinsulinemia and 
hyperglycemia are required for maximumly promoting hepatic glycogen synthesis [25], and 
therefore, it provides an optimal condition to detect potential differences in the rates of glycogen 
synthesis during the hyperinsulinemic clamp. Hepatic glycogen synthesis (specifically the direct 
pathway: glucose à glucose-6-phosphate à UDP glucose à glycogen) is the most robust in vivo 
flux indicator of direct insulin action on hepatic glucose metabolism, while the suppression of EGP 
is also influenced indirectly (i.e. independent of insulin signaling in liver) by insulin’s regulation of 
WAT lipolysis [2, 26]. Liver-specific PKCe KD led to an ~2-fold higher insulin-stimulated hepatic 
glycogen synthesis rate compared to the control group, resulting in higher post-clamp hepatic 
glycogen content (Figure 6C). 
We then assayed key components of the insulin signaling pathway and found that in rats 
treated with the liver-specific PKCe ASO, the improved hepatic insulin sensitivity was associated 
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with ~3-fold higher insulin-stimulated pIRK-Y1162 (Figure 6D). This in turn was accompanied by 
significant improvements in downstream insulin-stimulated Akt-S473, GSK3β-S9 and FOXO1-
S256 phosphorylation (Figures 6D and 6E). We also observed that there was markedly lower 
pIRK-T1160 levels with liver-specific PKCe KD compared to the control group (Figure 6F). 
Furthermore, with the same 4-day HFD feeding, rats with liver-specific PKCe KD had lower 
plasma glucose and insulin concentrations during an oral glucose tolerance test (oGTT) despite 
similar body weights (Figure 6G), demonstrating that hepatic PKCe activation contributes to HFD-
induced hyperglycemia and more prominently hyperinsulinemia during a physiological feeding 
behavior by directly mediating HIR. Additionally, in regular chow-fed rats, liver-specific PKCe KD 
abrogated acute DGAT2 KD’s induction of HIR during a hyperinsulinemic-hyperglycemic clamp 
(Figures 6H and 7G), indicating that hepatic PKCe is the necessary mediator of PM sn-1,2-DAG 
accumulation-induced HIR in the acute DGAT2 KD model. Liver-specific PKCe KD in regular 
chow-fed rats, however, did not further enhance hepatic insulin sensitivity (Figure 7H). 
Thus, liver-specific KD of PKCe with an MOE-GalNAc-modified liver-targeted ASO for 











Figure 6. Liver-Specific PKCe KD Ameliorates HFD- and Acute DGAT2 KD-Induced HIR 
(A) Hepatic and WAT PKCe protein content measured by western blot (top) and with its 
quantification (bottom). 
(B) EGP and its suppression by insulin during a hyperinsulinemic-hyperglycemic clamp in Ctrl 
versus hepatic PKCe KD rats. 
(C) Hepatic glycogen synthesis rate during a hyperinsulinemic-hyperglycemic clamp and post-
clamp hepatic glycogen content in Ctrl versus hepatic PKCe KD rats. 
(D) Levels of insulin-stimulated liver pIRK-Y1162, pAkt-S473 and (E) pGSK3β-S9 and pFOXO1-
S256 as measured by western blot (top) and with its quantification (bottom). 
(F) Levels of liver pIRK-T1160 as measured by western blot (top) and with its quantification 
(bottom) in Ctrl versus hepatic PKCe KD rats. 
(G) Fasted body weight, plasma glucose and insulin levels during an oGTT in Ctrl versus hepatic 
PKCe KD rats. 
(H) EGP, EGP’s suppression by insulin and hepatic glycogen synthesis rate during a 
hyperinsulinemic-hyperglycemic clamp and post-clamp hepatic glycogen content in Ctrl versus 
hepatic DGAT2 and PKCe KD rats. 
In all panels, data are the mean±S.E.M. In (A), (D), (E) and (F), n = 6 per group. In (B), (C) and 









Figure 7. Liver-Specific PKCe KD Hyperinsulinemic-Hyperglycemic Clamp 
(A) Fasted body weight, fasting and clamp insulin levels, plasma glucose and glucose infusion 
rate during clamp in HFD-fed Ctrl versus hepatic PKCe KD rats. 
(B) Plasma NEFA and its suppression by insulin during clamp in HFD-fed Ctrl versus hepatic 
PKCe KD rats. 
(C) Insulin-stimulated whole-body glucose turnover during clamp in HFD-fed Ctrl versus hepatic 
PKCe KD rats. 
(D) Liver triglyceride content in HFD-fed Ctrl versus hepatic PKCe KD rats. 
(E) Liver DAG stereoisomer content in five subcellular compartments in HFD-fed Ctrl versus 
hepatic PKCe KD rats. 
(F) Liver ceramide species content in five subcellular compartments in HFD-fed Ctrl versus 
hepatic PKCe KD rats. 
(G) Fasted body weight, fasting and clamp insulin levels, plasma glucose and glucose infusion 
rate during clamp in Ctrl versus hepatic DGAT2 + PKCe KD rats. 
(H) EGP, EGP’s suppression by insulin and hepatic glycogen synthesis rate during a 
hyperinsulinemic-hyperglycemic clamp and post-clamp hepatic glycogen content, fasted body 
weight, fasting and clamp insulin levels, plasma glucose and glucose infusion rate during clamp 
in regular chow diet-fed Ctrl versus hepatic PKCe KD rats. 
In all panels, data are the mean ± SEM. In (E) and (F), n = 6 per group. In all the other panels, n 
= 7 per group. *p < 0.05 and **p < 0.01.  
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Liver-Specific OE of Constitutively Active PKCe Induces HIR 
Taken together, these data so far demonstrate that PKCe is necessary for the development of sn-
1,2-DAG-mediated HIR. To determine whether PKCe activation per se is sufficient to cause HIR, 
we used an AAV vector to overexpress a constitutively active isoform of PKCe (PKCe-A159E) [27] 
driven by the liver-specific promoter, thyroxine binding globulin (TBG), in regular chow-fed rats. 
The A159E mutation prevents the binding of the pseudo-substrate domain to the catalytic domain, 
rendering the kinase constitutively active [27]. The AAV injection doubled the amount of total 
PKCe content in the liver with ~6-fold higher translocation without altering WAT PKCe content 
(Figure 8A). The higher hepatic content of constitutively active PKCe impaired insulin-stimulated 
hepatic glycogen synthesis by ~40% during a hyperinsulinemic-hyperglycemic clamp, resulting in 
lower post-clamp hepatic glycogen content (Figures 8B and 9A-9G). HIR was observed at the 
level of IRK, reflected by >50% lower insulin-stimulated pIRK-Y1162 levels, accompanied by 
impaired downstream insulin-stimulated Akt-S473, GSK3β-S9 and FOXO1-S256 phosphorylation 
in hepatic PKCe OE rats compared to the control group (Figures 8C and 8D). Furthermore, we 
also observed that there was ~2-fold higher pIRK-T1160 levels with liver-specific OE of 
constitutively active PKCe (Figure 8E). 
Despite marked reductions in hepatic insulin signaling and hepatic glycogen synthesis, 
hepatic OE of PKCe-A159E did not affect EGP during the clamp (Figure 9E). This result is 
consistent with prior studies demonstrating a relatively minor role for direct hepatic insulin 
signaling in regulating hepatic glucose production in mice and rats without hepatic steatosis and 
the critical role of insulin to suppress WAT lipolysis to regulate hepatic glucose production by the 
indirect pathway [2, 11, 28, 29]. Consistent with this model, plasma non-esterified fatty acid 
(NEFA) concentrations were equally suppressed by >90% in both groups resulting in near 
complete suppression of EGP in both groups during the clamp due to the indirect pathway 
regulation (Figure 9B). 
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 Taken together, these data support the sufficiency of hepatic PKCe in mediating HIR. 
Additionally, regular chow-fed rats with liver-specific OE of constitutively active PKCe had higher 
plasma glucose and insulin concentrations during an oGTT despite similar body weights (Figure 
8F), demonstrating that hepatic PKCe activation per se is sufficient to drive hyperglycemia and 











Figure 8. Liver-Specific OE of Constitutively Active PKCe Induces HIR 
(A) Hepatic PKCe protein content, hepatic PKCe translocation from cytosol to membrane and 
WAT PKCe content measured by western blot (top) and its quantification (bottom). 
(B) Hepatic glycogen synthesis rate during a hyperinsulinemic-hyperglycemic clamp and post-
clamp liver glycogen content in Ctrl versus hepatic PKCe OE rats. 
(C) and (D) Levels of insulin-stimulated liver pIRK-Y1162, pAkt-S473, pGSK3β-S9 and pFOXO1-
S256 as measured by western blot (top) and with its quantification (bottom). 
(E) Levels of liver pIRK-T1160 as measured by western blot (top) and with its quantification 
(bottom). 
(F) Fasted body weight, plasma glucose and insulin levels during an oGTT in Ctrl versus hepatic 
PKCe OE rats. 
In all panels, data are the mean±S.E.M. In (A), n = 5 or 7 per group. In (B), n = 8 per group. In 










Figure 9. Liver-Specific OE of Constitutively Active PKCe Hyperinsulinemic-Hyperglycemic 
Clamp 
(A) Fasted body weight, fasting and clamp insulin levels, plasma glucose and glucose infusion 
rate during clamp in Ctrl versus hepatic PKCe OE rats. 
(B) Plasma NEFA and its suppression by insulin during clamp. 
(C) Insulin-stimulated whole-body glucose turnover during clamp. 
(D) Liver triglyceride in Ctrl versus hepatic PKCe OE rats. 
(E) EGP and its suppression by insulin during clamp. 
(F) Liver DAG stereoisomer content in five subcellular compartments in Ctrl versus hepatic OE 
rats. 
(G) Liver ceramide species content in five subcellular compartments in Ctrl versus hepatic OE 
rats. 
In all panels, data are the mean ± SEM. In (F) and (G), n = 6 per group. In all the other panels, n 







NAFLD and HIR are both highly prevalent conditions that are strongly associated with each other, 
but the underlying molecular links between them remain widely debated. Multiple studies have 
reported the dissociation between hepatic triglyceride accumulation and HIR [12, 21, 22, 30-33], 
suggesting that triglycerides are likely not the mediating factor in causing HIR. Instead, among all 
the lipid species associated with NAFLD, DAGs and ceramides are the leading candidates 
thought to be involved [3-5, 28]. Since the mechanisms currently proposed for ceramides to 
induce hepatic insulin resistance target the distal insulin signaling steps (e.g. at the level of Akt) 
[3], they cannot explain the occurrence of proximal defects in hepatic insulin signaling at the level 
of the insulin receptor [13, 34]. 
We established the importance of PM sn-1,2-DAGs in the development of HIR using a 
model of acute DGAT2 KD. Since DGAT2 has been shown to be an ER-resident protein [35, 36], 
the accumulation of sn-1,2-DAGs in the ER following the acute hepatic DGAT2 KD is likely a 
direct result of transient substrate backup, while the extra DAGs are rapidly shuttled to other 
membrane compartments such as the PM, where they promote translocation of PKCe to the PM 
to induce insulin resistance. 
Consistent with the rodent studies, we found that liver PM sn-1,2-DAG content and pIRK-
T1160 levels also tracked with HIR in humans. The concomitant accumulation of PM sn-2,3-DAGs 
and sn-1,3-DAGs in the livers of individuals with HIR may simply reflect the condition of chronic 
excessive fatty acid supply, lipogenesis and/or lipolysis in the livers with NAFLD and likely does 
not contribute to the defects in hepatic insulin signaling. We also observed an accumulation of 
lipid droplet DAGs in liver samples from humans with HIR,  consistent with our prior report where 
we saw a similar accumulation in lipid droplet DAGs in liver samples of humans with HIR using a 
relatively crude three-compartment subcellular fractionation method [8]. However, this likely 
reflects the concurrent expansion of the lipid droplet pool in fatty liver in subjects with obesity 
 
 30 
under chronic conditions of increased substrate flux to the liver. Consistent with the hypothesis, 
we have previously demonstrated that this pool of lipid droplet DAGs does not contribute directly 
to HIR as demonstrated in a mouse model where CGI-58 ASO treated mice, with a marked 
accumulation of hepatic lipid droplet DAG content, were protected from lipid-induced HIR and 
manifested reduced hepatic PKCe translocation [21]. In addition, in the study of Ter Horst et al. 
[6], higher cytosolic DAGs were detected in human livers with HIR. However, the high cytosolic 
DAG content reported likely reflects contamination from lipid droplet and membrane fractions, 
while our new fractionation methodology utilized in the present study has been our best attempt 
to resolve content of DAGs and ceramides in different subcellular compartments. 
Our finding on the importance of PM sn-1,2-DAGs in mediating PKCe translocation, IRK-
T1160 phosphorylation and HIR is consistent with studies demonstrating that only sn-1,2-DAGs 
activate novel PKCs [18-20], as well as that the PM is the primary site of action for PKCe to induce 
HIR [13, 16]. Since lipid droplet lipolysis has been shown to produce mostly sn-2,3- and sn-1,3-
DAGs, which do not activate novel PKCs [37], our data could also provide an explanation for a 
few experimental models where CGI-58 and HSL (enzymes in lipolysis pathway) inhibition caused 
accumulation of DAGs (likely sn-2,3- and sn-1,3-DAGs) in the absence of PKCe activation and 
HIR [32, 38, 39]. 
In contrast to the consistent association between PM sn-1,2-DAGs and HIR, we observed 
no consistent association of any ceramide species in any subcellular compartment with HIR. This 
is consistent with prior studies that have dissociated hepatic ceramide content from HIR [7, 9, 40]. 
Multiple studies have suggested the involvement of PKCe in mediating lipid-induced HIR 
[8, 13-15], though many of the interventions used in these studies affected PKCe globally or in 
multiple tissues. In this regard, a recent study challenged the role of hepatic PKCe in regulating 
hepatic glucose metabolism [17]. Consistent with our prior study [13], Brandon et al. found that 
WAT PKCe has a role in the regulation of glucose metabolism. However, in contrast to the 
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conclusions of Brandon et al., we find that hepatic PKCe also has an important role in lipid-
mediated HIR and hypothesize that the discrepancies between our study and their study may be 
due to multiple technical issues. Firstly, as hepatic glucose production receives regulatory input 
from multiple sources in addition to the liver (e.g. WAT and skeletal muscle), and that insulin’s 
acute effects to suppress hepatic glucose production reflects insulin’s ability to directly stimulate 
hepatic glycogen synthesis and indirectly inhibit hepatic gluconeogenesis through inhibition of 
WAT lipolysis [2, 11, 26, 28, 29], it is essential to assess insulin’s direct activation of hepatic 
insulin signaling parameters (e.g. IRK-Y1162, Akt-S473, GSK3b-S9 and FOXO1-S256 
phosphorylation), as well as hepatic glycogen synthesis, to reliably assess the relatively subtle 
direct effects of insulin on hepatic glucose metabolism and HIR. Unfortunately, none of these 
parameters were assessed in the liver-specific PKCe knockout mice in the previous study [17]. 
Secondly, there may have been technical differences between the studies that preclude direct 
comparison. For example, the plasma glucose concentrations in some of the experiments of the 
previous study [17] were reported to be 12-13 mM for the basal state and increased to 30-35 mM 
during the GTTs. Despite this severe hyperglycemia, plasma insulin response curves during the 
GTTs were relatively flat without a physiological response to the extremely high plasma glucose 
concentrations, suggesting that these mice may have been stressed during the procedures, which 
in turn will mask any effects that PKCe may have on hepatic insulin action. Thirdly, the Cre-lox 
genetic knockout mouse model used in the previous study [17] may naturally produce different 
results compared to the short-term gene KD and OE rat models utilized in our studies due to 
potential developmental effects or strong compensatory effects in long-term genetic manipulation 
conditions. Finally, while it is possible that species differences might also explain the different 
observations, we do not think this is likely given that we and others have established a strong 
relationship between hepatic DAG content, PKCe translocation and HIR in mice [10, 41, 42] and 
most recently demonstrated that IRK-T1160A mice are protected from lipid-induced HIR [16]. 
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In order to address these limitations, we performed a series of studies in short-term 
genetically modified awake rats. There are multiple advantages and strengths of the awake rat 
model compared to the awake mouse model including the fact that rates of EGP and insulin-
stimulated whole-body glucose turnover in the awake rats are much closer to rates of EGP and 
turnover in humans than mice [2, 26], and compared to a life-long genetic knockout model, short-
term genetic modulation eliminates potential confounding developmental compensatory effects 
on hepatic insulin action. Using this approach, our results support both the necessity and 
sufficiency of hepatic PKCe activation in mediating HIR (Figure 10). 
Taken together with the fact that IRK-T1160 is highly conserved throughout evolution 
down to Drosophila melanogaster, we can hypothesize that the PM sn-1,2-DAG - PKCe - IRK-
T1160 axis may be evolutionarily preserved to limit insulin’s effects on promoting hepatic glycogen 
synthesis and reducing EGP during re-feeding following fasting and starvation with the intention 
to preserve blood glucose in favor of supporting central nervous system function [2]. Furthermore, 
given the presence of PKCe in other insulin responsive tissues, such as skeletal muscle and WAT, 
it is likely that PM sn-1,2-DAG activation of PKCe may also be playing a similar role in causing 
lipid-induced insulin resistance in these tissues. Finally, given that PKCe has multiple targets 
besides IRK-T1160, it is likely that PKCe activation may also impact additional downstream 
targets to alter insulin action in these tissues [43]. 
 
Limitations of Study 
The number of human liver samples from subjects with and without NAFLD and HIR were 
relatively small, and we were limited by the amount of tissue available from each biopsy. We 
therefore had to prioritize our analyses to yield the most novel information. We therefore prioritized 
these samples to assess DAG stereoisomers and ceramides in the five compartments in subjects 
with adequate liver tissues and subjected the rest of the tissue samples to an IRK-T1160 
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phosphorylation assay. Unfortunately, we did not have enough remaining tissues to assess PKCe 
translocation in these liver biopsies and future studies will be required to further address this 
relationship. However, we have previously established that increased PKCe translocation 
correlates with HIR in humans with NAFLD in the same cohort of human subjects [6].  
 Additionally, our study mostly investigated the importance of PM sn-1,2-DAGs and hepatic 
PKCe in relatively acute models of HIR. However, our data from human subjects suggest that the 
proposed model may also play an important role in long-term conditions of lipid-induced HIR 












Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
DGAT2 Santa Cruz Biotechnology Cat#sc-293211 
GAPDH Cell Signaling Technology Cat#5174 
pIRK-Y1162 Cell Signaling Technology Cat#3918 
IRK Cell Signaling Technology Cat#3025 
pAkt-S473 Cell Signaling Technology Cat#4060 
Akt Cell Signaling Technology Cat#2920 
pGSK3β-S9 Cell Signaling Technology Cat#5558 
GSK3β Cell Signaling Technology Cat#12456 
pFOXO1-S256 Cell Signaling Technology Cat#84192 
FOXO1 Cell Signaling Technology Cat#2880 
PKCe BD Biosciences Cat#610086 
Na-K ATPase Abcam Cat#ab7671 
pIRK-T1160 This paper N/A 
Calnexin Abcam Cat#ab22595 
VDAC Abcam Cat#ab14734 
Perilipin Cell Signaling Technology Cat#9349 
Bacterial and Virus Strains 
AAV8-TBG-eGFP Vector Biolabs SKU#VB1743 
AAV8-TBG-rPKCe(A159E) Vector Biolabs N/A 
Chemicals, Peptides, and Recombinant Proteins 
Human insulin Novo Nordisk NDC 0169-
1833-11 
[1,2,3,4,5,6,6-2H7]glucose Cambridge Isotopes Cat#DLM-2062 
[6,6-2H2]glucose Cambridge Isotopes Cat#DLM-349 
[1,2,3,4,5,6-13C6]glucose Cambridge Isotopes Cat#CLM-1396 
Somatostatin-14 Bachem Cat#H-1490 
Somatostatin-28 Bachem Cat#H-4955 
Amyloglucosidase Millipore-Sigma Cat#A7420 
Diacylglycerol concentration standard Indofine Chemical Cat#32-1902 
Ceramide concentration standard Avanti Polar Lipids Cat#860517P 
Critical Commercial Assays 
HR Series NEFA-HR (2) Color Reagent A Wako Cat#999-34691  
HR Series NEFA-HR (2) Solvent A Wako Cat#995-34791  
HR Series NEFA-HR (2) Color Reagent B Wako Cat#991-34891  
HR Series NEFA-HR (2) Solvent B Wako Cat#993-35191  
NEFA Standard Solution  Wako Cat#276-76491  
Triglyceride-SL reagent Sekisui Cat#236-99 
Experimental Models: Organisms/Strains 




MOE control ASO: 
CCTTCCCTGAAGGTTCCTCC 
Ionis Pharmaceuticals ISIS-141923 
DGAT2 ASO: 
GCATTACCACTCCCATTCTT 
Ionis Pharmaceuticals ISIS-369235 
MOE GalNAc control ASO: 
CCTTCCCTGAAGGTTCCTCC 
Ionis Pharmaceuticals ISIS-716837 
PKCe ASO: 
GCCAGCTCGATCTTGCGCCC 
Ionis Pharmaceuticals ISIS-1289956 
Software and Algorithms 







Regular chow diet Envigo Cat#2018 
High-fat diet Dyets Cat#112245 
 
Experimental Model and Subject Details 
Rat Models 
All animal studies were approved by the Yale University Institutional Animal Care and Use 
Committee and were performed in accordance with all regulatory standards. 150-250 g male 
Sprague-Dawley rats at ~6-8 weeks of age were purchased from Charles River Laboratories 
(Wilmington, MA) and were housed in the Yale Animal Resources Center at 23°C under 12-hour 
light (7:00am-7:00pm)/12-hour dark cycles (7:00pm-7:00am). The rats were fed ad libitum with 
free access to water and were in good health condition. Upon arrival from the vendor, the rats 
remained on their regular living condition without any experimental perturbations for at least 3-4 
days for acclimation and stress-minimization. The rats were group housed (2-3 per cage) until 
they underwent surgery under general isoflurane-induced anesthesia for insertion of polyethylene 
catheters in the common carotid artery (PE50 tubing, Instech Solomon, Plymouth Meeting, PA), 
the jugular vein (PE90 tubing, Instech) and the stomach (PE90 tubing, Instech) or injection of AAV 
solution into the portal vein, after which they were singly housed until time of killing. The rats were 
either fed with a regular chow diet (Harlan Teklad #2018, Indianapolis, IN) or a safflower oil-based 
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HFD with 60 kcal% from fat (Dyets #112245, Bethlehem, PA) for the amount of time as indicated 




Human subjects were recruited from the outpatient clinics of two obesity centers in the Amsterdam 
metropolitan area. Inclusion and exclusion criteria have been described [6]. Liver fat content was 
measured using proton magnetic resonance spectroscopy as described [6]. Insulin sensitivity was 
measured during a two-step hyperinsulinemic-euglycemic clamp using a stable isotope-labeled 
glucose tracer as described [6]. Liver biopsies were collected from the right liver lobe by an 
experienced surgeon during bariatric surgeries scheduled <2 weeks after clinical assessments. 
All human studies were approved by the Amsterdam University Medical Center medical ethics 
committee. The study was registered in the Netherlands Trial Register (NTR4666). All subjects 
provided written informed consent prior to inclusion. Please refer to Table S1 for the baseline 




At the end of all animal studies, rats were killed by intravenous pentobarbital sodium injection 
(150 mg/kg) with tissues and plasma collected for further analysis. Tissues were rapidly harvested 
and snap-frozen with clamps precooled in liquid nitrogen and then stored at -80°C for further 
analyses. For clamps, all tracers, insulin and glucose were infused via a catheter placed in the 
carotid artery at least one week before the study, and all blood collections were performed via a 
catheter placed in the jugular vein together with the arterial catheter. 
 For the DGAT2 ASO dosing, control and DGAT2 ASO (dissolved in PBS) were dosed 
once at the dose of 100 mg/kg via intraperitoneal (IP) injection two days before the clamp/tissue 
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collection studies. For the PKCe ASO dosing, control and PKCe ASO (dissolved in PBS) were 
dosed twice per week at the dose of 0.75 mg/kg via IP injection for three weeks prior to the 
clamp/oGTT/tissue collection studies. For the PKCe A159E AAV dosing, control (AAV8-TBG-
eGFP, dissolved in PBS with 5% glycerol) and PKCe A159E AAV (AAV8-TBG-rPKCe A159E, 
dissolved in PBS with 5% glycerol) were dosed once at the dose of 2e13 GC/kg via portal vein 
injection four weeks prior to the clamp/oGTT/tissue collection studies. 
 
Hyperinsulinemic-Glucose Clamps 
For the hyperinsulinemic-euglycemic clamp, after 14-16 hours of overnight fasting, [1,2,3,4,5,6,6-
2H7]glucose was infused at the rate of 0.1 mg/[kg-min] for 2 hours during basal infusion (-120 min 
to 0 min) to measure basal glucose turnover rates. Blood samples were collected at -20 min, -10 
min and 0 min to measure plasma glucose, insulin, NEFA concentrations and tracer atom percent 
excess (APE). Immediately after the basal infusion, insulin was infused at the rate of 4 mU/[kg-
min] to achieve physiological hyperinsulinemia during clamp (0 min to 120 min). At the same time, 
20% dextrose was infused at variable rates to maintain plasma glucose level at ~100-110 mg/dL. 
Infusion of [1,2,3,4,5,6,6-2H7]glucose continued at the rate of 0.1 mg/[kg-min] during the clamp to 
measure insulin-stimulated glucose turnover rates. Blood samples were collected at 100 min, 110 
min and 120 min to measure plasma glucose, insulin, NEFA concentrations and tracer APE. At 
the end of the clamp, rats were euthanized with tissues collected as described above. 
 For the hyperinsulinemic-hyperglycemic clamp, after 14-16 hours of overnight fasting, 
[6,6-2H2]glucose was infused at the rate of 0.1 mg/[kg-min] for 2 hours during basal infusion (-120 
min to 0 min) to measure basal glucose turnover rates. Blood samples were collected at -20 min, 
-10 min and 0 min to measure plasma glucose, insulin, NEFA concentrations and tracer APE. 
Immediately after the basal infusion, insulin was infused at the rate of 4 mU/[kg-min] achieve 
physiological hyperinsulinemia during clamp (0 min to 90 min). A 1:1 mixture of somatostatin-14 
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and somatostatin-28 (w/w) was also infused at the rate of 4 μg/[kg-min] to suppress endogenous 
insulin secretion. At the same time, 20% dextrose labeled with 50% [13C6]glucose was infused at 
variable rates to maintain plasma glucose level at ~150-160 mg/dL, measure rates of insulin-
stimulated hepatic glycogen synthesis and glucose turnover. Blood samples were collected at 10 
min, 20 min, 30 min, 40 min, 50 min, 60 min, 75 min and 90 min to measure plasma glucose, 
insulin, NEFA concentrations and tracer APE. At the end of the clamp, rats were euthanized with 
tissues collected as described above. 
 
Oral Glucose Tolerance Tests 
After 14-16 hours of overnight fasting, a single dose of 1 g/kg dextrose was injected via the gastric 
catheter placed at least one week before the study, and blood samples were collected at 0 min, 
15 min, 30 min, 45 min, 60 min, 90 min and 120 min via the jugular vein catheter placed together 
with the gastric catheter to measure plasma glucose and insulin levels. At the end of the oral 








− 15 ∗ 𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛	𝑟𝑎𝑡𝑒 
APE designates the atom percent enrichment measured by gas chromatography-mass 
spectrometry (GC-MS). Briefly, glucose samples were deproteinized with 1:1 ZnSO4:Ba(OH)2, 
derivatized with 1:1 acetic anhydride:pyridine (v/v) at 65°C with methanol added afterwards to 




 For the calculation of glycogen synthesis rates, liver glycogen m+6 APE (𝑋!"#
$%&'($)*) and 
plasma glucose m+6 APE (𝑋!"#
$%+'(,)) were determined by GC-MS. Liver UDP-glucose m+6 APE 
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-./0$%+'(,) ) was determined by liquid chromatography-MS/MS (LC-MS/MS). Rates of liver 


















 To measure liver total glycogen, liver samples were first homogenized in 0.6 N perchloric 
acid (PCA). Part of the homogenate was then neutralized with 1M KHCO3 and digested with 
amyloglucosidase (2 mg/mL) dissolved in acetate buffer (0.4 M, pH 4.8) for 2 hours at 37-40°C. 
Glucose levels were determined in samples before (free glycose) and after the amyloglucosidase 
digestion (total glucose) to calculate liver total glycogen content. 
 To measure liver glycogen m+6 APE, liver samples were ethanol-precipitated from PCA 
homogenates, dialyzed extensively against deionized water to remove free glucose before 
digested with amyloglucosidase. Digested glucose samples were then derivatized as described 
above prior to GC-MS analysis. 
 
Biochemical Analyses 
Plasma glucose was measured enzymatically using the YSI Glucose Analyzer (Yellow Springs, 
OH). Plasma insulin was measured by the Yale Diabetes Research Center Radioimmunoassay 
Core using radioimmunoassay. Plasma NEFA was measured using the enzymatic colorimetric 
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method by Wako reagents (Wako Diagnostics, Mountain View, CA). Liver triglyceride was first 
extracted with 2:1 chloroform:methanol (v/v). Samples were then mixed with sulfuric acid (1 M) 
and centrifugated to achieve phase separation. The organic phase was used to measure 
triglyceride content with the Sekisui triglyceride-SL reagent spectrophotometrically. Liver 
glycogen content measurement was described above. 
 
Tissue Analyses 
DAGs and ceramides were extracted from tissues with 2:1 chloroform:methanol (v/v) with 0.01% 
butylated hydroxytoluene. Known amounts of internal standards (1,2-dinonadecanoin for DAGs, 
N-heptadecanoyl-D-erythro-sphingosine for ceramides) were added during the extraction 
process. Afterwards, samples were dried down and re-dissolved in 95:5:0.5 hexane/methylene 
chloride/ethyl ether (v/v/v) before analyzed on LC/MS-MS as described below. 
 For western blots, tissues were homogenized in ice-cold homogenization buffer (20 mM 
Tris·HCl, pH 7.4, 5 mM EDTA, 0.25 mM EGTA, 10 mM Na4P2O7, 1% Nonidet P-40, and protease 
and phosphatase inhibitor mixtures; Roche Diagnostics) and centrifuged at 13,000 g at 4 °C for 
10 min to collect supernatant. Protein concentration was then determined by the Bradford method 
(Thermo Scientific). Protein samples were then diluted to 2 μg/μL with the addition of SDS buffer 
and β-mercaptoethanol and boiled for 5 min at 95°C. Afterwards, 20 μg of protein was loaded and 
resolved by SDS/PAGE using 4–12% gradient gels (Life Technologies) and transferred to 
polyvinylidene difluoride membranes (DuPont) using semi-dry transfer. Membranes were then 
blocked for 60 min at room temperature in 5% bovine serum albumin (BSA) and incubated 
overnight with primary antibody. After washing, membranes were incubated with horseradish 
peroxidase-conjugated secondary antibody (Cell Signaling Technology) for 1 hour. Detection was 
performed with enhanced chemiluminescence. 
 For assaying the IRK-T1160 phosphorylation, after protein concentration quantitation, 
protein samples were first immunoprecipitated by Dynabeads M-270 Epoxy (Invitrogen) 
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conjugated with D2 anti-IR alpha-subunit antibody. Primary antibody solution was diluted 1:100 – 
1:200 for pIRK-T1160 detection. 
 
PKCe Translocation Assay 
Tissue samples were homogenized in ice-cold buffer A (20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 
0.25 mM EGTA, 250 mM sucrose, and freshly added protease and phosphatase inhibitors, Roche 
Diagnostics). Debris was removed by centrifugation (5 min, 280 g, 4°C). Lysate was centrifuged 
(60 min, 100,000 g, 4°C), and an aliquot of the supernatant was saved as the cytosolic fraction. 
The pellet was washed once in ice-cold buffer B (250 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.25 
mM EGTA, 2% Triton X-100, and freshly added protease and phosphatase inhibitors). The pellet 
was resuspended in buffer B by sonication, incubated at 4°C for 45 minutes to solubilize 
membrane proteins, and centrifuged (60 min, 100,000 g, 4°C). An aliquot of the supernatant was 
saved as the membrane fraction. The resulting protein samples were subjected to western blot 
analysis as described above. The ratio between membrane PKCe (normalized to Na-K ATPase 
intensity) to cytosolic PKCe (normalized to GAPDH intensity) was calculated as an index of PKCe 
translocation. 
 
Five-Compartment Ultracentrifugation Fractionation 
The protocol was adapted and modified based on previous studies [44, 45]. Fresh tissues (60-
150 mg) were first homogenized in cold (4°C) TES buffer (250 mM sucrose, 10 mM Tris - pH 7.4, 
0.5 mM EDTA) with a Dounce homogenizer. The homogenate was then centrifuged (at 12,000 
rpm with SS-34 rotor or 17,000 g, 15 min, 4°C) to separate pellet A and supernatant A. The top 
lipid layer was collected as lipid droplet fraction. Pellet A was washed by being resuspended in 
TES buffer and centrifuged (at 12,000 rpm with SS-34 rotor or 17,000 g, 20 min, 4°C). Pellet A 
was then collected and resuspended in TES buffer and gently layered on top of 1.12 M sucrose 
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buffer cushion in ultracentrifuge tubes. The pellet A samples were then centrifuged (at 35,000 
rpm with TLS-55 rotor or 105,000 g, 20 min, 4°C) to separate pellet B, interface B and supernatant 
B. The interface B was collected, resuspended in TES buffer and centrifuged (at 37,000 rpm with 
TLA-100.2 rotor or 60,000 g, 9 min, 4°C) to obtain pellet C. Pellet C was then washed by being 
resuspended in TES buffer and centrifuged (at 37,000 rpm with TLA-100.2 rotor or 60,000 g, 9 
min, 4°C) and was designated as plasma membrane fraction. The pellet B was washed by being 
resuspended in TES buffer and centrifuged (at 12,000 rpm with SS-34 rotor or 17,000 g, 15 min, 
4°C) and was collected as mitochondria fraction. The supernatant A was centrifuged (at 65,000 
rpm with Ti-70.1 rotor or 390,000 g, 75 min, 4°C) to separate pellet D and supernatant D. Pellet 
D was washed by being resuspended in TES buffer and centrifuged (at 65,000 rpm with Ti-70.1 
rotor or 390,000 g, 60 min, 4°C) and was collected as the endoplasmic reticulum fraction. 
Supernatant D was collected as the cytosol fraction. 
 
Diacylglycerol Stereoisomer Separation and Quantitation  
Chiral analysis of DAGs were performed by LC-MS/MS using electrospray ionization on an AB 
Sciex Qtrap 6500 interfaced to Shimadzu UFLC with 2 LC-20AD pumps (and degassers), SIL-
20AC xR autosampler. Chromatographic separation was performed using Luna 5u Silica (100A, 
250x2.0mm) and LUX 5u Cellulose-1 (250x4.6mm) columns connected in series with an isocratic 
solvent of hexane:isopropanol (300:7) with a flow rate of 0.6 mL/min. TAGs elute between ~4 to 
8 minutes, and DAGs elute between ~11 and 17 minutes. For DAGs with the same FA 
composition, the order of elution was sn-1,3-DAG à sn-2,3-DAG à sn-1,2-DAG. For any specific 
stereoisomer (i.e., sn-1,2-DAG, sn-2,3-DAG, or sn-1,3-DAG) the order of elution generally 
increases with the degree of unsaturation. For example, C18:1 C18:1  à C18:1 C18:2 à C18:2 
C18:2. Standards were used to establish retention times, matrix effects, and response relative to 
the internal standard (1,2-Dinonadecanoin). No matrix effects were detected in the five subcellular 
compartments. However, the position of the FAs on the DAGs have not been established. For 
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example, for the sn-1,2-DAG assigned as C18:0 C16:0, C16:0 could be on either the sn-1 or the 
sn-2 position. In the process of optimization, it was found that the use of cartridges (e.g., DiOH) 
or silica TLC plates to pre-separate the DAGs from TAGs results leads to intramolecular trans-
esterification (e.g. the pre-separation of sn-1,2-DAGs will produce a mixture of sn-1,2-, sn-2,3-, 
and sn-1,3-DAGs). Thus, no additional separation steps following centrifugation to obtain cellular 
fraction were done prior to LC-MS/MS analysis. 
 
Generation of Rabbit-Mouse Chimeric Anti-pIRK-T1160 Monoclonal Antibody 
All experimental procedures involving animals were performed under a license granted by the 
national Danish authority, The Animal Experiment Inspectorate. Rabbits were immunized four 
times with a 1:1 mixture of CYEpTDY and YEpTDYC conjugated to keyhole limpet hemocyanin 
via the terminal cysteines. All immunizations were performed subcutaneously using 50 µg of 
antigen in Ribi adjuvant. Blood was drawn ten days after the last immunization and used for sera 
tests. Splenic B cells were harvested from rabbits with best titers and single-cell sorted on a Sony 
SH800 cell sorter using FITC-labelled anti-rabbit IgG (Jackson ImmunoResearch) and Biotin-
GGSGGSDIYEpTDYYRKG labelled with Streptavidin-PE (Jackson ImmunoResearch). Sytox red 
(Invitrogen) was included as a dead live stain. Sorted cells were expanded in vitro for 10 days on 
a layer of irradiated EL4-B5 cells, and the culture supernatant was harvested and used for ELISA 
screening. ELISA-positive clones were defined as binding the peptide used for immunization, but 
not binding the non-phosphorylated version of the same peptide. Hits were cloned as described 
in Lightwood et al. 2006 [46]. In short, the heavy/light chain variable regions were cloned using 
RT-PCR with gene specific primers and the amplicons inserted into an expression vector 
containing mouse IgG1/kappa constant regions. The construct was expressed in HEK cells, and 
the specificity of the chimeric rabbit/mouse antibody was validated by ELISA. 
 
Quantification and Statistical Analysis  
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Most of our data follow normal distribution, and comparisons were performed using the unpaired 
2-tailed Student’s t-test, with significance defined as a p value < 0.05. For data that do not follow 
normal distribution, non-parametric test was used to calculate the p value. GraphPad Prism 8.0 
(San Diego, CA) was used for all statistical analysis. In most cases, n = 6-8 per group, unless 
otherwise indicated in the figure legends. Data are presented as the mean ± SEM.  
All the tracer APE analyses (measured by GC-MS), DAG and ceramide content analyses 
(measured by LC-MS/MS) and insulin level assays were performed in a blinded fashion. For the 
animal studies, sample sizes were preselected using power calculation. Exclusion was applied 
only when the technical procedure failed (e.g. catheter failure causing inability to complete the 

























White adipose tissue (WAT) insulin action promotes GLUT4-mediated WAT glucose uptake and 
suppresses lipolysis (Figure 11). Obesity-related metabolic diseases such as type 2 diabetes 
(T2D) and metabolic-associated fatty liver disease (MAFLD) are often accompanied by WAT 
dysfunction [2, 47]. One aspect of WAT dysfunction is WAT insulin resistance, which is partially 
characterized by insulin’s reduced ability to suppress lipolysis, resulting in higher rates of fatty 
acid delivery to liver and skeletal muscle [2, 48]. Ectopic lipid accumulation in insulin-responsive 
tissues such as liver and skeletal muscle leads to insulin resistance via the accumulation of 
diacylglycerol (DAG) in the plasma membrane (PM) and subsequent translocation and activation 
of novel PKCs (nPKCs) [1, 2, 13]. In liver, accumulation of sn-1,2-DAGs in the PM activates PKCe 
which then phosphorylates insulin receptor kinase (IRK) at T1160 to impair IRK’s activation and 
subsequent activation of downstream signaling events [2, 13, 16, 49]. This model can explain the 
development of lipid-induced liver and skeletal muscle insulin resistance in obese rodents and 
humans [1, 2, 13, 16, 49-52] as well as the mechanism by which weight loss [40], adiponectin 
[53], and liver-targeted mitochondrial uncouplers reverse insulin resistance in high-fat diet (HFD)-
fed obese [9, 54] and lipodystrophic [10] insulin-resistant rodents. 
Despite of these insights into insulin resistance in other tissues, the pathogenesis of WAT 
insulin resistance remains unclear. Multiple factors have already been implicated, including low-
grade inflammation, altered adipokine secretion and hypoxia [29, 55, 56]. However, further studies 
have suggested that WAT insulin resistance can develop early following overfeeding as a primary 
event. For example, overfed human subjects can develop peripheral insulin resistance prior to 





Figure 11. White Adipose Tissue Insulin Signaling 
The binding of insulin triggers insulin receptor’s activation through its dimerization and 
autophosphorylation on critical tyrosine residues. Activated insulin receptor recruits and activates 
a series of downstream effects to promote GLUT4-mediated white adipose tissue glucose uptake 



















Short-Term Overnutrition Induces White Adipose Tissue Insulin Resistance through sn-1,2-






Similar to its critical role in lipid-induced hepatic insulin resistance, PKCe appears to be also 
important in the pathogenesis of white adipose tissue (WAT) insulin resistance. Silencing of both 
hepatic and WAT PKCe with an antisense oligonucleotide improved WAT insulin action, reflected 
by increased insulin-stimulated WAT glucose uptake in high-fat diet (HFD)-fed rats [13]. 
Consistent with these results, Brandon and colleagues recently demonstrated improvement of 
glucose tolerance in HFD-fed WAT-specific PKCe knockout mice [17]. However, they did not 
document any alterations in the WAT insulin signaling pathway or in insulin’s suppression of WAT 
lipolysis in these mice [17]. Furthermore, there was no conclusion on whether the diacylglycerol 
(DAG) - PKCe - insulin receptor kinase (IRK)-T1160 pathway was involved in WAT insulin action 
regulation or whether another distinct molecular pathway is regulated by PKCe activation to 
impact glucose tolerance. In this study, we examine the hypothesis that the DAG - PKCe - IRK-
T1160 pathway serves as an early contributor to short-term HFD-induced WAT insulin resistance 
which hinders the ability of insulin to suppress WAT lipolysis and promote WAT glucose uptake. 
In order to test this hypothesis, we first explored this pathway in male Sprague Dawley 
rats fed with HFD versus regular chow diet (RC) for 7 days, a time frame in which HFD feeding 
may induce WAT insulin resistance without causing WAT inflammation in rats [29]. We measured 
the content of DAG stereoisomers in five subcellular compartments – plasma membrane (PM), 
endoplasmic reticulum (ER), mitochondria (Mito), cytosol (C) and lipid droplet (LD), assayed the 
translocation of different PKCs and the activation of certain key steps in insulin signaling pathway. 
We further quantified the impact of WAT insulin resistance with a hyperinsulinemic-euglycemic 
clamp (HEC) study, using a combination of stable and radiolabeled isotope tracers to measure 
the alterations in whole-body and WAT fatty acid flux and glucose metabolism. Furthermore, to 
determine whether phosphorylation of IRK-T1160 is necessary for lipid-induced WAT insulin 
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resistance, we performed the same HEC with stable and radiolabeled isotope tracers in WT 




Seven-Day HFD Causes WAT Insulin Resistance 
We performed a HEC combined with [2H7]glucose, [2H5]glycerol and [13C16]palmitate infusions in 
male Sprague-Dawley rats fed with either RC or a 7-day HFD (Figures 12A and 12B). There was 
no significant difference in body weight, fasting plasma glucose and insulin concentrations 
between the RC and HFD group (Table 2). We quantified fatty acid and glycerol turnover in the 
basal (fasted) state and 30 min after a primed (25 mU/kg-min x 5 min), continuous (2.5 mU/kg-
min) insulin infusion. This short HEC clamp was sufficient to establish a steady state in fatty acid 
and glycerol turnover (Figures 12C and 12D) and allowed us to study changes in insulin action 
and signaling mediating the suppression of WAT lipolysis. There were no significant differences 
in fasting non-esterified fatty acid (NEFA) concentrations or rates of whole-body lipolysis between 
the groups (Figures 12E, 13A, 13C and 13E). However, after 7-day HFD, the ability of insulin to 
suppress WAT lipolysis was impaired, and we observed less suppression of NEFA concentration 
(76±3% versus 54±6%, p < 0.001, Figures 13A and 13B). Consistent with these results, we found 
that insulin’s suppression of whole-body glycerol turnover (46±5% versus 23±4%, p < 0.01, 
Figures 13C and 13D) and fatty acid turnover (37±2% versus 23±3%, p < 0.001, Figures 12E, 
12F, 13E and 13F) during the HEC clamp were also impaired with 7-day HFD feeding. Further, 
we performed a 140-min HEC to quantify insulin-stimulated glucose uptake in WAT. Rats fed with 
a 7-day HFD exhibited a ~50% reduction in insulin-stimulated WAT glucose uptake (Figures 12G, 
12H and 13G). 
In summary, 7 days of HFD feeding caused WAT insulin resistance reflected by reductions 
















Parameters RC 7-day HFD 
Body weight (g) 309.0 ± 4.6 315.9 ± 4.5 
Basal plasma glucose (mg/dL) 118.9 ± 4.80 113.0 ± 2.5 
Basal plasma insulin (µU/mL) 7.3 ± 1.5 9.7 ± 1.3 
Clamp plasma glucose (mg/dL) 112.6 ± 4.1 123.3 ± 5.0 
Clamp plasma insulin (µU /mL) 75.7 ± 4.9 78.5 ±7.4 
 
Table 2. Characteristics of the Rats in Hyperinsulinemic-Euglycemic Clamp 
Data are presented as mean ± SEM of n = 8-10 per group, with comparisons by the 2-tailed 
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Figure 12. Hyperinsulinemic-Euglycemic Clamp in RC- versus 7-Day HFD-Fed Rats 
(A) and (B) Time course of plasma glucose and glucose infusion rates during a 30-min 
hyperinsulinemic-euglycemic clamp. 
(C) and (D) Whole-body palmitate turnover and its suppression by insulin during the clamp. 
(E) and (F) Time course of glycerol m+5 APE and palmitate m+16 APE during the clamp. 
(G) and (H) Time course of plasma glucose and glucose infusion rates during a 140-min HEC. 
In all panels, data are the mean ± SEM of n = 6-10 per group, with comparisons by 2-tailed 










Figure 13. Seven-Day HFD Causes WAT Insulin Resistance as Reflected by Reductions in 
WAT Glucose Uptake and Insulin’s Suppression of WAT Lipolysis 
(A) Plasma NEFA under basal (overnight fasting) and hyperinsulinemic-euglycemic clamp 
conditions. 
(B) Insulin’s suppression of plasma NEFA during the clamp. 
(C) and (D) Whole-body glycerol turnover and its suppression by insulin during the 
hyperinsulinemic-euglycemic clamp. 
(E) and (F) Whole-body fatty acid turnover and its suppression by insulin during the 
hyperinsulinemic-euglycemic clamp. 
(G) Insulin-stimulated WAT glucose uptake. 
In all panels, data are the mean ± SEM of n = 7-10 per group, with comparisons by 2-tailed 






Seven-Day HFD Impairs Insulin-Stimulated Signaling Cascade Activation in WAT 
We next explored potential mechanisms by which HFD impairs insulin’s suppression of WAT 
lipolysis by examining the components of the insulin signaling cascade that regulate the key 
lipolytic enzymes in epididymal WAT. Insulin-stimulated phosphorylation of both IRK and Akt were 
decreased in HFD-fed rats compared to the RC group (Figures 14A and 14B), suggesting that 
the defect in insulin action could be attributed to impaired IRK activation. The canonical pathway 
by which insulin suppresses WAT lipolysis is mainly through activation of phosphodiesterase 3B 
(PDE3B), which then degrades cyclic adenosine monophosphate (cAMP) to halt PKA-mediated 
phosphorylation of lipolytic enzymes, leading to decreased activity of HSL and reduced LD 
protection from perilipin. Thus, we measured insulin-stimulated PDE3B phosphorylation, cAMP 
level and PKA activity in WAT. Rats subjected to 7-day HFD exhibited decreased insulin-
stimulated phosphorylation of PDE3B, and this was associated with higher cAMP levels and PKA 
activity in WAT (Figures 14C-14E). These changes were associated with increased 
phosphorylation of key lipolytic proteins - hormone-sensitive lipase (HSL) at S660, perilipin at 
S522, and adipose triglyceride lipase (ATGL) at S406 (Figures 14F-14H). Basal levels of these 
key WAT insulin signaling proteins were unchanged (Figure 15E). 
In summary, 7 days of HFD-feeding impaired insulin signaling in WAT at the level of IRK, 















Figure 14. Seven-Day HFD Feeding Impairs Insulin-Stimulated Signaling Cascade 
Activation in WAT and is Associated with Increases in Plasma Membrane sn-1,2-DAG 
Content and PKCe Translocation 
(A), (B) and (C) Insulin-stimulated phosphorylation of IRK, Akt and PDE3B in WAT. 
(D) and (E) WAT cAMP level and PKA activity during the hyperinsulinemic-euglycemic clamp. 
(F), (G) and (H) Insulin-stimulated phosphorylation of HSL, perilipin and ATGL. 
(I) WAT PKCe translocation as measured by its membrane / cytosol ratio. 
(J) Separation of five subcellular compartments in WAT – plasma membrane (PM), mitochondria 
(Mito), endoplasmic reticulum (ER), cytosol (C) and lipid droplet (LD). 
(K) WAT sn-1,2-DAG content in five subcellular compartments. 
In (A)-(H) panels, samples (after overnight fasting) were under hyperinsulinemic-euglycemic 
clamp conditions. Data are the mean ± SEM of n = 5-10 per group. In (I)-(K) panels, samples 
were under 6-hr fasting basal condition, data are the mean ± SEM of n = 4-5 per group. In all 














Figure 15. DAG Compartmental Profile in WAT of RC- versus 7-Day HFD-Fed Rats 
(A) WAT total DAG proportion in five subcellular compartments. 
(B) WAT total DAG content in five subcellular compartments. 
(C) WAT sn-2,3-DAG content in five subcellular compartments. 
(D) WAT sn-1,3-DAG content in five subcellular compartments. 
(E) WAT protein content in basal condition. 
In all panels, samples were under basal condition (6-hr fasting), data are the mean ± SEM of n = 











Table 3. WAT sn-1,2-DAG Individual Species Content in RC- versus 7-Day HFD-Fed Rats 




(nmol/g) PM Mito ER
Species RC HFD P RC HFD P RC HFD P
C16:0 C16:0 0.077 ± 0.008 0.166 ± 0.018 0.004 0.220 ± 0.008 0.205 ± 0.062 0.789 0.814 ± 0.039 0.854 ± 0.234 0.855
C16:0 C18:2 0.155 ± 0.006 0.349 ± 0.031 0.001 0.451 ± 0.032 0.436 ± 0.095 0.874 1.846 ± 0.570 2.525 ± 0.985 0.550
C18:1 C16:0 0.065 ± 0.004 0.137 ± 0.011 0.001 0.188 ± 0.002 0.169 ± 0.045 0.654 0.689 ± 0.178 0.864 ± 0.381 0.667
C18:0 C16:0 0.020 ± 0.003 0.031 ± 0.002 0.022 0.033 ± 0.001 0.035 ± 0.007 0.739 0.102 ± 0.004 0.122 ± 0.030 0.487
C16:0 C20:4 0.003 ± 0.000 0.005 ± 0.001 0.038 0.008 ± 0.002 0.005 ± 0.002 0.310 0.017 ± 0.004 0.018 ± 0.003 0.810
C18:2 C18:2 0.028 ± 0.003 0.111 ± 0.021 0.007 0.138 ± 0.019 0.160 ± 0.018 0.447 0.620 ± 0.262 1.301 ± 0.482 0.229
C18:1 C18:2 0.063 ± 0.005 0.124 ± 0.018 0.019 0.196 ± 0.021 0.188 ± 0.028 0.818 0.721 ± 0.243 1.033 ± 0.371 0.489
C18:1 C18:1 0.083 ± 0.003 0.119 ± 0.016 0.080 0.183 ± 0.011 0.171 ± 0.042 0.778 0.631 ± 0.178 0.767 ± 0.278 0.680
C18:2 C18:0 0.024 ± 0.002 0.048 ± 0.004 0.003 0.053 ± 0.005 0.054 ± 0.007 0.855 0.177 ± 0.044 0.259 ± 0.078 0.363
C18:1 C18:0 0.016 ± 0.002 0.022 ± 0.001 0.035 0.028 ± 0.002 0.023 ± 0.005 0.380 0.105 ± 0.020 0.116 ± 0.038 0.800
C18:0 C18:0 0.131 ± 0.003 0.129 ± 0.005 0.711 0.111 ± 0.003 0.118 ± 0.003 0.175 0.130 ± 0.010 0.119 ± 0.007 0.451
C18:0 C20:4 0.013 ± 0.007 0.021 ± 0.009 0.562 0.013 ± 0.003 0.021 ± 0.005 0.189 0.036 ± 0.007 0.028 ± 0.004 0.386
sn-1,2-DAGs 
(nmol/g) Cytosol LD
Species RC HFD P RC HFD P
C16:0 C16:0 0.134 ± 0.027 0.141 ± 0.036 0.883 5.294 ± 1.182 4.835 ± 1.247 0.799
C16:0 C18:2 0.284 ± 0.094 0.396 ± 0.202 0.606 21.89 ± 5.269 27.98 ± 6.847 0.496
C18:1 C16:0 0.138 ± 0.038 0.145 ± 0.049 0.915 8.339 ± 1.994 8.753 ± 2.270 0.894
C18:0 C16:0 0.022 ± 0.003 0.027 ± 0.004 0.307 0.729 ± 0.173 0.802 ± 0.240 0.807
C16:0 C20:4 0.005 ± 0.001 0.003 ± 0.001 0.135 0.108 ± 0.030 0.138 ± 0.031 0.514
C18:2 C18:2 0.065 ± 0.028 0.175 ± 0.094 0.256 8.132 ± 2.155 17.33 ± 4.614 0.093
C18:1 C18:2 0.075 ± 0.025 0.137 ± 0.071 0.390 7.727 ± 1.939 11.27 ± 2.905 0.328
C18:1 C18:1 0.088 ± 0.027 0.122 ± 0.036 0.473 7.821 ± 2.015 9.702 ± 2.860 0.597
C18:2 C18:0 0.036 ± 0.012 0.041 ± 0.017 0.785 1.594 ± 0.400 2.467 ± 0.680 0.283
C18:1 C18:0 0.015 ± 0.002 0.015 ± 0.005 0.995 1.051 ± 0.280 1.248 ± 0.392 0.687
C18:0 C18:0 0.118 ± 0.004 0.108 ± 0.004 0.130 0.312 ± 0.051 0.308 ± 0.054 0.960
C18:0 C20:4 0.011 ± 0.006 0.004 ± 0.001 0.385 0.058 ± 0.016 0.079 ± 0.019 0.414
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Seven-Day HFD Increases WAT PM sn-1,2-DAG Content and PKCe Translocation 
Both HFD-induced WAT insulin resistance and hepatic insulin resistance have an insulin signaling 
defect at the level of IRK activation. In liver, impaired IRK activation is attributed to activation of 
PKCe, and we hypothesized that a short-term HFD may also lead to activation of PKCe in WAT. 
As there is little data on the role of PKCs in regulating WAT physiology, we first assayed the 
activation of certain major PKC isoforms. Specifically, we measured translocation (from cytosol 
to membrane, an index of activation) of both conventional and novel PKC isoforms in WAT in RC 
versus 7-day HFD-fed rats. The translocation of PKCe, as reflected by its membrane / cytosol 
ratio, increased by ~two-fold in HFD-fed rats compared to the RC-fed group (Figure 14I). In 
contrast, the membrane translocation of other PKC isoforms including α, β, θ and δ were unaltered 
by the 7-day HFD feeding (Figures 16A-16D). PKCs are activated by DAGs, specifically, sn-1,2-
DAGs [18-20]. DAGs are present in multiple subcellular compartments, such as the ER, Mito, PM, 
LD and cytosol. Thus, we developed an assay to separate five subcellular compartments in WAT 
(Figure 14J). Next, we measured the concentration of DAG stereoisomers in each fraction. As 
expected, approximately 90% of total DAG were located in the lipid droplet fraction (Figure 15A). 
There were no differences in total DAG and sn-2,3-, sn-1,3-DAG concentrations between the 
groups (Figure 15B-15D). However, we observed an ~two-fold increase of sn-1,2-DAG content in 
the PM compartment (Figure 14K, Table 3). This was specifically associated with WAT PKCe 
membrane translocation (Figure 14I) but not translocation of other isoforms (Figures 16A-16D). 
These changes occurred without evidence of WAT inflammation. Expression of genes associated 
with WAT inflammation and hypoxia were unchanged (Figure 16E). 
Taken together, these data suggest that activation of the PKCe pathway, by a short-term 
HFD, is triggered by accumulation of PM-associated sn-1,2-DAGs and that the sn-1,2-DAG - 









Figure 16. Translocation of PKCs and Expression of Genes Related to Inflammation and 
Hypoxia in WAT of RC- versus 7-Day HFD-Fed Rats 
(A) WAT PKCa translocation as measured by its membrane / cytosol ratio. 
(B) WAT PKCb translocation as measured by its membrane / cytosol ratio. 
(C) WAT PKCq translocation as measured by its membrane / cytosol ratio. 
(D) WAT PKCd translocation as measured by its membrane / cytosol ratio. 
(E) Expression of WAT genes associated with inflammation and hypoxia. 
In all panels, rats were under basal condition (6-hr fasting), data are the mean ± SEM of n = 4-6 






IRKT1150A Mice Are Protected from A 7-Day HFD-Induced WAT Insulin Resistance 
We had previously identified IRK-T1160 (human homolog of mouse IRK-T1150) as a specific 
residue that is phosphorylated by PKCe in the liver [16]. Phosphorylation of this residue decreases 
the tyrosine kinase activity of IRK and its activation of downstream signaling events. Mutation of 
this residue from a threonine to an alanine (i.e. IRKT1150A) shields IRK from this pathogenic 
phosphorylation and preserves hepatic insulin signaling and hepatic insulin sensitivity in HFD-fed 
mice [16]. In our previous study we did not observe any alterations in WAT insulin action in HFD-
fed IRKT1150A mice [16]. However, those assessments of WAT metabolism were performed during 
the final stages of a 140-min hyperinsulinemic-euglycemic clamp with an insulin infusion rate of 
2.5 mU/(kg-min). Suppression of WAT lipolysis occurs rapidly after the onset of hyperinsulinemia 
[29], and the degree of WAT insulin resistance after just several days of HFD feeding is subtle 
and can be surmounted with high plasma insulin concentrations. Thus, any differences in WAT 
lipolysis may have been obscured in our previous studies involving the IRKT1150A mice. 
In order to address this possibility, we performed a much shorter 30-min hyperinsulinemic-
euglycemic clamp study with a lower-dose insulin infusion rate [2.0 mU/(kg-min)] to evaluate WAT 
insulin action in IRKT1150A mice subjected to 7-day HFD (Figures 17A-17E). As observed 
previously, there were no significant differences in body composition, overnight fasting plasma 
glucose, insulin and NEFA concentrations as well as whole-body rates of WAT lipolysis between 
the WT and IRKT1150A group (Table 4, Figures 17A-17F, 18A, 18C and 18E). Nevertheless, 
IRKT1150A mice retained the ability of insulin to suppress WAT lipolysis as reflected by lower plasma 
NEFA concentration, whole-body glycerol turnover and fatty acid turnover (Figures 17G and 18A-
18F) during the hyperinsulinemic-euglycemic clamp. In addition, WAT insulin signaling was 
preserved in IRKT1150A mice, reflected by higher insulin-stimulated IRK-Y1162 phosphorylation 
and Akt-S473 phosphorylation compared to HFD-fed WT mice (Figures 19A and 19B). We also 
examined the impact of 7-day HFD feeding on the downstream proteins that regulate WAT 
lipolysis. In contrast to the WT mice subjected to 7-day HFD feeding, IRKT1150A mice displayed 
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increased PDE3B activity, which subsequently resulted in lower cAMP levels and thereby lower 
PKA activity (Figures 19C-19E). Consequently, phosphorylation of HSL, perilipin and ATGL is 
lower in IRKT1150A mice (Figures 19F-19H), consistent with the preservation of insulin-mediated 
suppression of WAT lipolysis. These data demonstrate that phosphorylation of IRK-T1160 is 
required for the development of WAT insulin resistance after a 7-day HFD. Taken together with 
our prior studies [9, 10, 13, 16, 40, 49-54], these findings suggest that lipid-induced liver, muscle 
and WAT insulin resistance develop as a consequence of a common pathway involving increases 
in plasma membrane sn-1,2-DAG content leading to PKCe activation and the consequent 





Parameters     WT   IRKT1150A 
Body weight (g) 24.4 ± 0.9 23.6 ± 0.4 
Fat mass (g) 2.7 ± 0.4 2.4 ± 0.2  
Basal plasma glucose (mg/dL) 128.5 ± 11.9 126.8 ± 4.9 
Basal plasma insulin (µU/mL) 8.5 ± 0.6 8.3 ± 0.9 
Clamp plasma glucose (mg/dL) 98 ± 7.4 103 ± 6.8 
Clamp plasma insulin (µU/mL) 36.1 ± 4.7 38.9 ± 4.2 
 
Table 4. Characteristics of WT versus IRKT1150A Mice in Hyperinsulinemic-Euglycemic 
Clamp  
Data are presented as mean ± SEM of n = 6 per group, with comparisons by the 2-tailed 










Figure 17. Hyperinsulinemic-Euglycemic Clamp in HFD-Fed WT versus IRKT1150A Mice 
(A) and (B) Time course of plasma glucose and glucose infusion rates. 
(C) and (D) Body weight and fat mass. 
(E) Plasma insulin concentrations under basal and clamp conditions. 
(F) and (G) Whole-body palmitate turnover and its suppression by insulin during the 
hyperinsulinemic-euglycemic clamp. 
In all panels, data are the mean ± SEM of n = 6 per group, with comparisons by 2-tailed unpaired 













Figure 18. IRKT1150A Mice Retain Insulin’s Ability to Suppress WAT Lipolysis After 7-Day 
HFD 
(A) Plasma NEFA under basal (overnight fasting) and hyperinsulinemic-euglycemic clamp 
conditions. 
(B) Insulin’s suppression of plasma NEFA during the hyperinsulinemic-euglycemic clamp. 
(C) and (D) Whole-body glycerol turnover and its suppression by insulin during the 
hyperinsulinemic-euglycemic clamp. 
(E) and (F) Whole-body fatty acid turnover and its suppression by insulin during the 
hyperinsulinemic-euglycemic clamp. 
In all panels, data are the mean ± SEM of n = 5-6 per group, with comparisons by 2-tailed unpaired 








Figure 19. IRKT1150A Mice Are Protected from HFD-Induced WAT Insulin Resistance 
(A)-(C) Insulin-stimulated phosphorylation of IRK, Akt and PDE3B in WAT. 
(D) and (E) WAT cAMP level and PKA activity during the clamp. 
(F)-(H) Insulin-stimulated phosphorylation of HSL, perilipin and ATGL. 
In all panels, mice (after overnight fasting) were under hyperinsulinemic-euglycemic clamp 
condition, data are the mean ± SEM of n = 6 per group, with comparisons by 2-tailed unpaired 







Appropriate energy storage and release in healthy WAT is critical for survival under calorie scarce 
conditions as well as for proper nutrient distribution during feeding. Under conditions of 
overnutrition this process is dysregulated, especially in individuals with inherited predisposition to 
restrained adipocyte capacity [59]. Insulin regulates energy storage in WAT, in part by 
suppressing lipolysis. Dysregulated WAT lipolysis (along with a decreased capacity for adipocyte 
expansion) could promote ectopic lipid accumulation and, consequently, insulin resistance in liver 
and skeletal muscle [1, 2, 60-62]. Increased WAT lipolysis will also increase hepatic 
gluconeogenesis by providing increased delivery of glycerol and NEFA to the liver, which in turn 
will both promote increased gluconeogenesis [2, 29]. As such, insulin’s regulation of WAT lipolysis 
serves as a key component in the network of inter-organ communication and regulation of hepatic 
glucose production [2, 29]. Defects in insulin’s suppression of WAT lipolysis may occur early 
during the transition from insulin-sensitive to insulin-resistant, with defects detectable as early as 
7-10 days of HFD feeding in rodents [21]. This early defect precedes other well-characterized 
changes in the adipocytes (i.e. inflammation, hypoxia, necrosis, etc.) which will also promote 
dysregulated WAT metabolism and increased lipolysis. The data presented here now provide a 
mechanistic underpinning for this phenomenon. Specifically, the PM sn-1,2-DAG - PKCe - IRK-
T1160 pathway that is responsible for lipid-induce hepatic insulin resistance, which occurs in 
nonalcoholic fatty liver disease (NAFLD), may also account for lipid-induced WAT insulin 
resistance in the early stage of overnutrition.  
Firstly, impaired WAT insulin signaling occurs rapidly during HFD feeding. We detected 
WAT insulin resistance after only 7 days of HFD feeding with impaired insulin-mediated WAT 
glucose uptake and suppression of WAT lipolysis, which was accompanied by impaired activation 
of key insulin signaling steps initiating at the level of IRK tyrosine auto-phosphorylation. 
Importantly, this subtle development of WAT insulin resistance manifests earlier than other 
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alterations such as inflammation and hypoxia in epididymal WAT, which may predispose WAT to 
more severe metabolic disturbances with prolonged HFD feeding.  
WAT insulin resistance can be attributed to a proximal defect in insulin signaling at the level 
of IRK which ultimately impacts the regulation of key lipolytic enzymes. The defect in IRK 
activation leads to impaired Akt and PDE3B phosphorylation. As a consequence, the decrease in 
PDE3B activity permits higher levels of cAMP which then promotes PKA activity. PKA directly 
phosphorylates and activates HSL [63, 64]. PKA also phosphorylates perilipin, which promotes 
the release of CGI-58 (a key co-effector of ATGL) and the recruitment of HSL to LDs [65]. Some 
have proposed that insulin may regulate WAT lipolysis in an Akt-independent pathway. Choi et 
al. demonstrated a noncanonical Akt-independent, phosphoinositide-3 kinase-dependent 
pathway regulating WAT lipolysis by selectively altering PKA targets perilipin and HSL [66]. This 
pathway would also be impacted by the proximal defect in IRK activation and thus is consistent 
with our proposed model of WAT insulin resistance.  
Short-term HFD feeding increases the content of sn-1,2-DAGs in the PM of adipocytes. 
Though an adipocyte is mainly comprised of a massive lipid droplet, important signaling lipids are 
also present in other subcellular compartments. Here we assessed the content of DAG 
stereoisomers in five WAT subcellular compartments. As expected, LD was the largest reservoir 
of DAGs accounting for ~90% of total DAGs. However, in epididymal WAT, there was no 
difference in LD sn-1,2-DAG content following short-term HFD feeding. In contrast, the PM DAGs 
account for only ~1% of total DAGs in WAT, but HFD feeding caused an approximately two-fold 
increase in PM sn-1,2-DAG content. 
sn-1,2-DAGs are the primary DAG product of the re-esterification pathway, while previous 
studies demonstrated that sn-2,3- and sn-1,3-DAGs are primarily generated through the lipolytic 
pathway [37]. Therefore, a short-term HFD condition will likely promote more accumulation of sn-
1,2-DAGs due to the increased flux of fatty acids into the re-esterification pathway. As for the 
compartment specificity, it’s likely that in short-term HFD (e.g. 7-day), the other membrane 
 
 76 
compartments – ER and mitochondria have the ability to maintain a relatively steady pool of lipids, 
due to their relatively larger baseline lipid content and/or higher lipid handling capacity (transport 
or oxidation), while PM has a relatively small baseline lipid content and therefore is more prone 
to relatively large fold changes in sn-1,2-DAGs. In LDs, DAGs mostly originate from lipolysis, and 
since basal rates of lipolysis do not change under this condition, DAG content in LDs is not 
expected to change very much. However, in long-term (e.g. chronic HFD) conditions, DAG 
content will likely increase in LDs and potentially other subcellular compartments. 
 The two-fold increase in PM sn-1,2-DAGs was associated with an approximately two-fold 
increase in PKCe translocation which has previously been implicated to play a role in WAT insulin 
action. PKCe antisense oligonucleotide treatment improved insulin-stimulated WAT glucose 
uptake in 3-day HFD-fed rats [13]. Consistent with these results, Brandon et al. found that WAT-
specific PKCe knockout mice displayed improved glucose tolerance on HFD, indicating that WAT 
PKCe activation may be an essential step in the development of WAT insulin resistance [17]. 
However, there are some notable differences between the study of Brandon et al. and the present 
work. Brandon et al. reported that WAT-specific deletion of PKCe improved glucose tolerance in 
chronically HFD-fed mice, but they did not detect alterations in insulin’s regulation of WAT lipolysis 
or insulin-stimulated glucose uptake in WAT explant after 1-week HFD. They also did not detect 
differences in plasma fatty acid concentrations during a glucose tolerance test. In contrast, our 
relatively low-dose hyperinsulinemic-euglycemic clamp studies, combined with stable isotopic 
measurements of lipolytic rates, provided us with a more sensitive approach to detect differences 
in insulin’s regulation of WAT lipolysis in vivo. 
We have previously identified IRK-T1160 as a specific target phosphorylated by PKCe, 
leading to inhibition of IRK activity in the liver [16]. Phosphorylation of the T1160 residue in IRK 
activation loop is predicted to destabilize its active configuration, thereby inhibiting IRK activity. 
As such, IRKT1150A mice are protected from HFD-induced hepatic insulin resistance [16]. WAT is 
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exquisitely sensitive to the antilipolytic effects of insulin [67] and thus we were most likely unable 
to detect differences in WAT insulin action due to the saturating dose of insulin administered in 
our prior hyperinsulinemic-euglycemic clamp studies in the IRKT1150A mice. In order to address 
this issue, we used a lower insulin infusion rate [2.0 mU/(kg-min) versus 2.5 mU/(kg-min)] for a 
shorter time (30 min versus 140 min) in the current study to better assess WAT insulin action in 
WT versus IRKT1150A mice. Under this new experimental condition, we demonstrated that IRKT1150A 
mice were protected from HFD-induced WAT insulin resistance. WAT insulin signaling was 
preserved at the level of IRK activity down through Akt phosphorylation, thereby preserving 
insulin’s ability to suppress phosphorylation of perilipin, HSL and ATGL through regulating PDE3B 
activity and cAMP content. In summary, we demonstrated that PKCe-mediated IRK-T1160 
phosphorylation mediates lipid-induced WAT insulin resistance by inhibiting IRK activity. 
Taken together, these data demonstrate that PM sn-1,2-DAG - PKCe - IRK-T1160 
phosphorylation is a critical pathway in the pathogenesis of short-term HFD-induced WAT insulin 
resistance (Figure 20). Alterations in this pathway may occur during the early stage of WAT lipid 
over-influx, resulting in impaired insulin’s regulation of WAT lipolysis and glucose uptake. Though 
the defect in WAT is subtle, it may be a necessary predisposition to more severe WAT dysfunction 
as well as for ectopic lipid deposition and insulin resistance in liver and skeletal muscle in more 
prolonged states of overnutrition. 
Furthermore, given that PKCe has many additional targets in addition to IRK-T1160, it is 
likely that PM sn-1,2-DAG induced PKCe activation will impact many additional targets that affect 
WAT lipid and glucose metabolism independent of changes in insulin receptor kinase activity [43]. 
Thus, longer-term studies are needed to investigate if eliminating WAT insulin resistance could 
ameliorate other metabolic disturbances and whether these results translate to humans under 
conditions of short-term overnutrition and obesity. Moreover, these data identify the PM sn-1,2-
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DAG - PKCe - IRK-T1160 phosphorylation pathway as a new potential therapeutic target to treat 















All animal studies were approved by the Yale University Institutional Animal Care and Use 
Committee and were performed in accordance with all regulatory standards. Male Sprague-
Dawley rats weighing approximately 250g were obtained from Charles River Laboratories 
(Wilmington, MA) and were maintained on a 12-hour light/12-hour dark cycle. After 1 week of 
acclimation, rats underwent surgery for placement of polyethylene catheters in the common 
carotid artery (PE50 tubing, Instech Solomon, Plymouth Meeting, PA) and the jugular vein (PE90 
tubing, Instech), and then fed either a regular chow diet (Harlan Teklad #2018, Madison, WI: 18% 
calories from fat, 58% from carbohydrate, 24% from protein) or a high-fat diet (Dyets #112245, 
Bethlehem, PA: 59% calories from fat, 26% from carbohydrate, 15% from protein), ad lib for 7 
days. 
Mice were generated and housed in the Yale Animal Resources Center under a 12-hour 
light/12-hour dark cycle and received ad libitum access to food and water. IRKT1150A mice were 
generated as previously reported [16]. Male mice were studied at 14-18 weeks of age. Catheters 
were placed in the jugular vein 7-9 days before the hyperinsulinemic-euglycemic clamp. Mice 
were fed either a regular chow diet (Harlan Teklad #2018: 18% fat, 58% carbohydrate, and 24% 
protein) or a high-fat diet (Research Diets D12492: 60% fat, 20% carbohydrate, and 20% protein). 
 
Hyperinsulinemic-Euglycemic Clamps 
After either 7 days of regular chow or high-fat diet feeding, rats were fasted overnight. The rats 
underwent a basal intra-arterial prime infusion of [1,2,3,4,5,6,6-2H7]glucose [1.5 mg/(kg-min)], 
[13C16]palmitate [0.5 mg/(kg-min)] and [1,1,2,3,3-2H5]glycerol [1.5 mg/(kg-min)] for 5 min, followed 
by a continuous infusion at rate of 0.15 mg/(kg-min), 0.05 mg/(kg-min) and 0.15 mg/(kg-min) 
respectively for 115 min. Blood samples were taken from the jugular vein catheter at 100, 110, 
and 120 min of the basal infusion for measurement of lipid turnover. A short (30 min) 
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hyperinsulinemic-euglycemic clamp was then conducted starting with a primed/continuous 
infusion of human insulin [prime 25 mU/(kg-min) for 5 min, continuous 2.5 mU/(kg-min)] and a 
variable infusion of 20% dextrose to maintain euglycemia (~110mg/dL). Blood samples were 
drawn from the venous catheter at 10, 20, 30 min of the clamp, with 20 and 30min time points to 
measure clamp lipid turnover. Plasma insulin levels at the 120 min of basal infusion and 30 min 
of the clamp were measured by radioimmunoassay in the Yale Diabetes Research Center. 
GC/MS was used to measure plasma glycerol and palmitate atom percent excess (APE), as we 
have described [29], as well as calculating rates of lipolysis by correcting for the percentage of 
individual fatty acid content among the content of total fatty acids. Glycerol and palmitate turnover 
was calculated as (𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 = C<35')3	=/>
/%5,!5	=/>
− 1D ∗ 𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛	𝑟𝑎𝑡𝑒 ). Another set of 140-min clamp 
study was performed as previously described [13]. A 200 μCi bolus of 2-deoxy-[1-14C]-glucose 
(PerkinElmer) was injected at 120-min to monitor tissue-specific insulin-stimulated glucose 
uptake. For the assay of WAT glucose uptake, WAT samples were homogenized, and the 
supernatants were transferred to an ion-exchange column to separate 14C-2-deoxyglucose-6-
phosphate from 2-deoxy-[1-14C]-glucose as previously described [68]. At the end of the clamp, 
rats were euthanized with pentobarbital sodium (150 mg/kg), and tissues were immediately 
harvested and frozen with tongs pre-cooled in liquid N2. Tissues and plasma were stored at -80 
°C for subsequent analyses. 
For the mouse clamp, study cohorts consisted of homozygous male IRKT1150A mice and 
littermate male WT controls which were generated by our group [16]. After 7 days of high-fat 
feeding, mice were fasted overnight. Awake mice under gentle tail restraint were first infused with 
[13C16]palmitate [0.3 mg/(kg-min)] and [2H5]glycerol [0.075 mg/(kg-min)] for 120 minutes to 
measure lipid turnover. A short (30 min) hyperinsulinemic-euglycemic clamp was then performed 
with a primed, continuous infusion of human insulin [prime 4.8 mU/(kg-min) for 3 min, continuous 
2.0 mU/(kg-min)] and a variable infusion of 20% dextrose to maintain euglycemia (~120 mg/dL). 
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At the end of the clamp, mice were euthanized with pentobarbital sodium (150 mg/kg), and tissues 
were immediately harvested and snap-frozen in liquid N2. Tissues and plasma were stored at -80 
°C for subsequent analyses. 
 
Biochemical Analysis 
Plasma glucose concentrations were measured using the YSI Glucose Analyzer (Yellow Springs, 
OH). Plasma insulin was measured by radioimmunoassay. Plasma NEFA concentration was 
measured spectrophotometrically using a Wako reagent (Wako Diagnostics). cAMP was 
measured by cAMP ELISA kit (Enzo Life Science) in accordance with the protocol. PKA activity 
was measured by PKA colorimetric activity kit (Invitrogen). 
 
Immunoblotting and IP 
WAT lysates were prepared in RIPA buffer with protease inhibitors (cOmplete MINI, Roche) and 
phosphatase inhibitors (PhosSTOP, Roche). Protein was measured by the BCA assay (Pierce) 
and equal amount of protein extraction was mixed with sample buffer containing 5% β-
mercaptoethanol. After running the samples in 4% to 12% Tris-glycine gels (Novex), proteins 
were electrotransferred to Immobilon P PVDF membranes (Millipore) by semi-dry transfer. 
Membranes were blocked in 5% BSA for 1 hour at room temperature and then probed overnight 
at 4°C with primary antibodies. The antibodies were obtained from Cell Signaling Technology 
(IRK: Cat#3025, pIRK-Y1162: Cat#3918, Akt: Cat#2920, pAkt-S473: Cat#4060, perilipin: 
Cat#9349, HSL: Cat#4107, pHSL-S660: Cat#4126, ATGL: Cat#2138, GAPDH: Cat#5174); 
abcam (pATGL-S406: Cat#ab135093, Na-K ATPase: Cat#ab7671, Calnexin: Cat#ab22595, 
VDAC: Cat#ab14734); ThermoFisher (PDE3B: Cat#14-1973-82); FabGennix International 
Incorporated (pPDE3B: Cat#PPD3B-140AP); VALA Sciences (pPerilipin-S522: Cat#4856) and 
BD Biosciences (PKCe: Cat#610086). Membranes were then washed in TBST and incubated for 
1 hour at room temperature with secondary antibodies (Cell Signaling). After washing in TBST for 
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three times, antibody binding was detected by enhanced chemiluminescence (Pierce). Films were 
developed within the linear dynamic range of signal intensity and then were scanned for digital 
analysis. Densitometry was performed using ImageJ software.  
IP was performed using 1-2 mg protein from lysates prepared as described above, the lysate 
was incubated with antibody PDE3B (ThermoFisher) overnight for 16 hours and then mixed with 
protein A/G agarose beads (Santa Cruz Biotechnology Inc.) for 4 hours. Immune complexes were 
washed extensively in lysis buffer and eluted in Laemmli buffer for immunoblot analysis. 
 
PKCe Translocation Assay 
PKCe membrane / cytosol ratio in freeze clamped WAT was assessed by western blot as 
previously reported [15] with slight modifications and assumed to represent PKCe activity in WAT. 
Briefly, 400-500 mg WAT from rats fasted for 6 hours was homogenized in ice-cold buffer A 
containing 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.25 mM EGTA, 250 mM sucrose with protease 
inhibitors (cOmplete MINI, Roche). Lysate was centrifuged (60 min, 100,000 g, 4°C) to separate 
the membrane and cytosol from lipid droplet. The supernatant was saved as the cytosolic fraction. 
The pellet was washed once in ice-cold buffer A to remove all the lipid droplet and cytosol and 
then was resuspended in buffer B containing 250 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.25 mM 
EGTA, 2% Triton X-100 with protease inhibitors by sonication, incubated at 4°C for 45 minutes to 
solubilize membrane proteins, and centrifuged (60 min, 100,000 g, 4°C). The supernatant was 
saved as the membrane fraction. Equal amounts of protein were subjected to measure 
PKCe membrane / cytosol ratio by immunoblotting. 
 
DAG Subcellular Fractionation Assay 
Subcellular fractionation was performed as described previously [44] with modifications. 300-350 
mg epididymal WAT were first homogenized in cold (4°C) TES buffer (250 mM sucrose, 10 mM 
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Tris - pH 7.4, 0.5 mM EDTA) with a Dounce-type tissue grinder (Kontes no. 21). All subsequent 
centrifugation steps were performed at 4°C. The homogenate was centrifuged at 12,000 rpm (or 
17,000 g) in an SS-34 rotor for 15 min to separate pellet A and supernatant A (including the top 
lipid layer). Pellet A was washed by being resuspended in buffer A and centrifuged at 12,000 rpm 
(or 17,000 g) in an SS-34 rotor for 20 min. Pellet A was then resuspended in buffer A and layered 
on top of 1.12 M sucrose solution in a 2 mL ultracentrifuge tube and was centrifuged in a TLS-55 
rotor at 35,000 rpm (or 105,000 g) for 20 min to separate interface B and pellet B. Interface B was 
collected and resuspended with buffer A and then centrifuged in a TLA-100.2 rotor at 37,000 rpm 
(or 60,000 g) for 9 min to obtain pellet C. Pellet C was washed by being resuspended in buffer A 
and centrifuged in a TLA-100.2 rotor at 37,000 rpm (or 60,000 g) for 9 min and was saved as 
plasma membrane fraction. Pellet B was washed by being resuspended in buffer A and 
centrifuged at 12,000 rpm (or 17,000 g) in an SS-34 rotor for 15 min and was collected as 
mitochondrial fraction. Supernatant A was centrifuged at 65,000 rpm (or 390,000 g) in Ti-70.1 
rotor for 75 min to separate pellet D, supernatant D (collected as cytosol fraction) and the top lipid 
layer (collected as lipid droplet fraction). Pellet D was washed by being resuspended in buffer A 
and centrifuged at 65,000 rpm (or 390,000 g) in Ti-70.1 rotor for 60 min and was collected as ER 
fraction. DAGs were extracted from the five compartmentations and measured by LC-MS/MS as 
described previously [21, 49]. 
Statistical Analysis 
Comparisons were performed using the 2-tailed Student’s t-test, unpaired with significance 
defined as a p value < 0.05. GraphPad Prism 8.0 (San Diego, CA) was used for all statistical 
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